Status:
ACTIVE_NOT_RECRUITING
Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease
Lead Sponsor:
Angel Argiles
Collaborating Sponsors:
Medical University Innsbruck
Klinikum Bayreuth GmbH
Conditions:
Chronic Kidney Disease(CKD)
Progression, Disease
Eligibility:
All Genders
18-85 years
Brief Summary
The goal of this longitudinal observational study is to estimate the performances of a candidate proteomic biomarker to identify patients at short term risk of chronic kidney disease (CKD) progression...
Eligibility Criteria
Inclusion
- Male or female patients
- over 18 years and below 85 years of age at recruitment
- Chronic kidney disease (CKD)
- eGFR of 25-65 mL/min/1.73m2 (CKD-EPI formula)
- Beneficiary of health insurance
- Must be able to communicate with the investigator
- Written informed consent must be provided before participation.
Exclusion
- History of renal transplantation
- Current episode of Acute Kidney Injury
- Any clinically significant disorder, which in the Investigator's opinion could interfere with the results of the trial.
- Known or suspected abuse of alcohol or narcotics
- Current pregnancy
- Inability to give written informed consent
- Protected adults
Key Trial Info
Start Date :
May 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT06962891
Start Date
May 2 2023
End Date
May 1 2026
Last Update
July 24 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Medizinische Universität Innsbruck
Innsbruck, Austria, 6020
2
Néphrologie Dialyse St Guilhem
Sète, France, 34200
3
Klinikum Bayreuth GmbH
Bayreuth, Germany, 95445